Search - tctmd.com

Displaying 481 - 500 of 1009

Sort: Relevancy | Date

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

April 02, 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

Hope for these hard-to-treat patients: more than half saw ≥ 50% decrease at 24 weeks, regardless of LDL receptor function.

News Conference News ACC 2020

Evinacumab Cuts LDL Cholesterol in Homozygous FH

Yael L. Maxwell

April 01, 2020

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Presentation ACC 2020

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Presenter: Deepak L. Bhatt

March 30, 2020

ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up

News Conference News ACC 2020

ISCHEMIA in Print: New MI Data and More Calls for Longer Follow-up

March 30, 2020

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

News Conference News ACC 2020

Diabetes May Boost Benefits of COMPASS Dual Antithrombotic Approach

March 28, 2020

COMPASS Antithrombotic Approach Works Well in Prior-PCI Patients

News Daily News

COMPASS Antithrombotic Approach Works Well in Prior-PCI Patients

March 27, 2020

Cardiac Considerations Amid COVID-19: Shared Stories May Save Lives

News Daily News

Cardiac Considerations Amid COVID-19: Shared Stories May Save Lives

March 25, 2020

Missed Opportunities: Many HF Patients Not Tested for CAD

News Daily News

Missed Opportunities: Many HF Patients Not Tested for CAD

March 20, 2020

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

News Daily News

Ideal CV Health Over the Long Term Linked With Better Survival, Less Disease

Michael O'Riordan

March 13, 2020

Type 2 MI Linked to More CV Deaths, Even in Younger Patients

News Daily News

Type 2 MI Linked to More CV Deaths, Even in Younger Patients

March 04, 2020

Snapshot of Revascularization Outcomes Offers Some Reassurances, Some Surprises

News Daily News

Snapshot of Revascularization Outcomes Offers Some Reassurances, Some Surprises

February 14, 2020

News Daily News

Long-term Evolocumab Safe, Effective for Familial Hypercholesterolemia Treatment

Yael L. Maxwell

February 12, 2020

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

News Daily News

Stent-Related Adverse Events Continue Out to 5 Years: Meta-analysis

Michael O'Riordan

February 10, 2020

Trials of New Cancer Drugs Failing to Address Potential CV Risks

News Daily News

Trials of New Cancer Drugs Failing to Address Potential CV Risks

February 10, 2020

Patient-Level Data Strengthen Rosiglitazone-CV Link: Meta-analysis

News Daily News

Patient-Level Data Strengthen Rosiglitazone-CV Link: Meta-analysis

February 07, 2020

Ticagrelor Hits Mark in Large Stroke Study: THALES Top-line Results

News Daily News

Ticagrelor Hits Mark in Large Stroke Study: THALES Top-line Results

Michael O'Riordan

January 27, 2020

Hypertension Starts Years Earlier in Women Than Men, Serial BP Shows

News Daily News

Hypertension Starts Years Earlier in Women Than Men, Serial BP Shows

January 17, 2020

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

News Daily News

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Michael O'Riordan

January 14, 2020

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.